−0.0951USD
−2.79 MUSD
63.42 KUSD
34.42 M
About Intellipharmaceutics International Inc.
Sector
CEO
Isa Odidi
Headquarters
Toronto
Website
Founded
1998
ISIN
CA4581733090
FIGI
BBG000C0S7F3
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a controlled-release drug delivery platform that can be applied to the development of pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company was founded by Isa Odidi and Amina Odidi on October 22, 2009 and is headquartered in Toronto, Canada.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IPCIF is 0.0600 USD — it has decreased by 14.29% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Intellipharmaceutics International Inc. stocks are traded under the ticker IPCIF.
Intellipharmaceutics International Inc. is going to release the next earnings report on Apr 19, 2024. Keep track of upcoming events with our Earnings Calendar.
IPCIF stock is 50.00% volatile and has beta coefficient of −0.16. Check out the list of the most volatile stocks — is Intellipharmaceutics International Inc. there?
IPCIF earnings for the last quarter are −0.10 USD per share, whereas the estimation was −0.38 USD resulting in a 74.79% surprise. The estimated earnings for the next quarter are −0.20 USD per share. See more details about Intellipharmaceutics International Inc. earnings.
Intellipharmaceutics International Inc. revenue for the last quarter amounts to 1.18 M USD despite the estimated figure of 1.82 M USD. In the next quarter revenue is expected to reach 2.74 M USD.
Yes, you can track Intellipharmaceutics International Inc. financials in yearly and quarterly reports right on TradingView.
IPCIF stock hasn't changed in a week, the month change is a 14.29% fall, over the last year Intellipharmaceutics International Inc. has showed a 20.00% increase.
IPCIF net income for the last quarter is −1.86 M USD, while the quarter before that showed −54.08 K USD of net income which accounts for −3.35 K% change. Track more Intellipharmaceutics International Inc. financial stats to get the full picture.
Today Intellipharmaceutics International Inc. has the market capitalization of 2.03 M, it has decreased by 0.09% over the last week.
No, IPCIF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IPCIF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Intellipharmaceutics International Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Intellipharmaceutics International Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Intellipharmaceutics International Inc. stock shows the sell signal. See more of Intellipharmaceutics International Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Intellipharmaceutics International Inc. EBITDA is −2.32 M USD, and current EBITDA margin is −4.00 K%. See more stats in Intellipharmaceutics International Inc. financial statements.